TUSI, a new drug blend also known as “pink cocaine,” is gaining traction across Latin America, Europe, and more recently, in the United States. Despite its nickname, this bright pink powder rarely contains actual cocaine or the 2C-series psychedelics it references. Instead, tusi samples often include ketamine mixed with substances like MDMA, methamphetamine, cocaine, opioids, and other psychoactive compounds. Thus, treating patients who have used tusi becomes complex.
The confusion surrounding tusi’s ingredients poses substantial risks. With most users expecting a psychedelic experience from 2C-type drugs, they’re often unaware of the actual substances involved. This lack of knowledge can lead to unintended drug exposures, heightening the risk of adverse effects. Moreover, tusi’s varying composition complicates research efforts, as underreported usage of drugs like ketamine or MDMA can lead to skewed data on drug consumption patterns.
While popular for its color and marketing, tusi’s shifting ingredients raise concerns for health professionals and drug researchers alike. Experts stress the need for awareness campaigns aimed at those at risk, educating them about the unpredictability of tusi’s contents. Researchers, on the other hand, may need to incorporate toxicology screenings alongside self-reported drug data to more accurately capture the scope of tusi use and its impact.
This evolving landscape emphasizes the importance of reliable information for both consumers and scientists. Understanding and addressing the rise of tusi is essential for healthcare providers aiming to deliver informed care, effective treatment, and proactive public health measures in the face of this emerging trend and evolving drug landscape.
Reference: Palamar JJ. Tusi: a new ketamine concoction complicating the drug landscape. 2023;49(5):546-550.
Anaya Malik | AMJ
